Ignite Creation Date:
2024-05-06 @ 4:11 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04894409
Status:
COMPLETED
Last Update Posted:
2021-05-20
First Post:
2021-05-16
Brief Title:
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
Sponsor:
Cluster de Bioeconomia de Baja California AC
Organization:
Cluster de Bioeconomia de Baja California AC
Study Overview
Official Title:
Evaluation of Silver Nanoparticles as an Oropharyngeal Product Mouthwash and Nasal Hygiene by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVID-19
Brief Summary:
In this research silver nanoparticles AgNPs were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells Subsequently the investigators assessed the effects of mouthwash and nose rinse with ARGOVIT silver nanoparticles AgNPs in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital Mexico a hospital for the exclusive recruitment of patients diagnosed with COVID-19
Detailed Description:
SARS-CoV-2 infection in hospital areas is of a particular concern since the close interaction between health care personnel and patients diagnosed with COVID-19 which allows virus to be easily spread between them and subsequently to their families and communities Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic In a first step silver nanoparticles AgNPs were tested in vitro to determine an inhibitory effect on SARS-CoV-2 infection in cultured cells Subsequently the investigators assess the effects of mouthwash and nose rinse with ARGOVIT silver nanoparticles AgNPs in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital Mexico a hospital for the exclusive recruitment of patients diagnosed with COVID-19 The investigators present a prospective randomized study of 231 participants that was carried out for 9 weeks during the declaration of a pandemic The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution the control group was instructed to do mouthwashes and nose rinse in a conventional way
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None